Q2 2025 Revvity Inc Earnings Call Transcript
Key Points
- Revvity Inc (RVTY) achieved 3% organic growth in Q2 2025, in line with expectations, driven by strong performance in the Life Sciences segment.
- The Signals Software franchise experienced approximately 30% growth, setting a new record for orders in a single quarter.
- Revvity Inc (RVTY) reported adjusted EPS of $1.18, which was above expectations and guidance.
- The company generated $115 million in free cash flow during the quarter, maintaining a solid 90% conversion rate year-to-date.
- Revvity Inc (RVTY) repurchased nearly $300 million worth of stock in Q2, bringing total repurchases to nearly $450 million for the first half of the year.
- The Diagnostics segment faced challenges in China due to changes in hospital lab reimbursement policies, impacting the Immunodiagnostics business.
- Revvity Inc (RVTY) lowered its full-year organic growth outlook to 2% to 4%, down 1% from prior expectations.
- The company anticipates a meaningful pullback in its Immunodiagnostics business in China for the remainder of the year.
- Operating margins were pressured by lower volumes of high-margin diagnostic tests and recent changes in FX rates.
- The academic and government customer segment continued to show weakness, with revenue declining in the low single digits year over year.
Welcome, and thank you for standing by. Today's conference call will begin shortly. (Operator Instructions)
Hello, everybody, and welcome to the Q2 2025 Revvity earnings conference call. My name is Elliot, and I'll be your coordinator for today. (Operator Instructions)
I'd now like to hand over to Steve Willoughby, Senior Vice President of Investor Relations. Please go ahead.
Thank you, operator. Good morning, everyone, and welcome to Revvity's second-quarter 2025 earnings conference call. On the call with me today are Prahlad Singh, our President and Chief Executive Officer; and Max Krakowiak, our Senior Vice President and Chief Financial Officer.
I'd like to remind you of the Safe Harbor statements outlined in our press release issued earlier this morning and those in our SEC filings. Statements or comments made on this call may be forward-looking statements, which may include, but may not be limited to, financial projections or other statements of the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
